WO2009072626A1 - ヘテロ環化合物による造血幹細胞の増幅方法 - Google Patents

ヘテロ環化合物による造血幹細胞の増幅方法 Download PDF

Info

Publication number
WO2009072626A1
WO2009072626A1 PCT/JP2008/072190 JP2008072190W WO2009072626A1 WO 2009072626 A1 WO2009072626 A1 WO 2009072626A1 JP 2008072190 W JP2008072190 W JP 2008072190W WO 2009072626 A1 WO2009072626 A1 WO 2009072626A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
positive cell
hematopoietic stem
stem cell
cell
Prior art date
Application number
PCT/JP2008/072190
Other languages
English (en)
French (fr)
Inventor
Takanori Nakamura
Atsushi Miyamura
Taito Nishino
Norihisa Ishiwata
Katsuaki Miyaji
Original Assignee
Nissan Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Industries, Ltd. filed Critical Nissan Chemical Industries, Ltd.
Priority to EP08856980A priority Critical patent/EP2233561A4/en
Priority to JP2009544754A priority patent/JP5573161B2/ja
Priority to US12/746,507 priority patent/US9115341B2/en
Publication of WO2009072626A1 publication Critical patent/WO2009072626A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

　本発明は、生物学的に安全かつ廉価にて製造可能な低分子化合物を利用し、ＣＤ３４陽性細胞を生体外で従来よりも効率的かつ短期間に増幅することを課題とする。本発明のさらなる課題は、造血幹細胞及び／又は造血前駆細胞の機能不全に伴う各種の造血系疾患に対する治療方法として有用である、ＣＤ３４陽性細胞の増幅剤を提供することにある。 　式（１）（式中の、Ａ、Ｂ、Ｌ１、Ｌ２、Ｌ３、Ｌ４、Ｒ１、Ｒ２、Ｒ３、Ｘ及びＹは、本文中において定義される。）で表される化合物、該化合物の互変異性体若しくはその医薬的に許容され得る塩又はそれらの溶媒和物の存在下、ＣＤ３４陽性細胞を生体外で培養することを特徴とするＣＤ３４陽性細胞の増幅方法。
PCT/JP2008/072190 2007-12-05 2008-12-05 ヘテロ環化合物による造血幹細胞の増幅方法 WO2009072626A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08856980A EP2233561A4 (en) 2007-12-05 2008-12-05 METHOD FOR AMPLIFYING HEMATOPOIETIC STRAIN CELL USING HETEROCYCLIC COMPOUND
JP2009544754A JP5573161B2 (ja) 2007-12-05 2008-12-05 ヘテロ環化合物による造血幹細胞の増幅方法
US12/746,507 US9115341B2 (en) 2007-12-05 2008-12-05 Method for expanding hematopoietic stem cells using heterocyclic compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007315168 2007-12-05
JP2007-315168 2007-12-05

Publications (1)

Publication Number Publication Date
WO2009072626A1 true WO2009072626A1 (ja) 2009-06-11

Family

ID=40717804

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/072190 WO2009072626A1 (ja) 2007-12-05 2008-12-05 ヘテロ環化合物による造血幹細胞の増幅方法

Country Status (5)

Country Link
US (1) US9115341B2 (ja)
EP (1) EP2233561A4 (ja)
JP (1) JP5573161B2 (ja)
KR (1) KR101585276B1 (ja)
WO (1) WO2009072626A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010140685A1 (ja) * 2009-06-04 2010-12-09 日産化学工業株式会社 ヘテロ環化合物及び造血幹細胞の増幅剤
JPWO2009072624A1 (ja) * 2007-12-05 2011-04-28 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
JPWO2009072625A1 (ja) * 2007-12-05 2011-04-28 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
WO2012060388A1 (ja) * 2010-11-02 2012-05-10 日産化学工業株式会社 アミノ安息香酸誘導体の有機アミン塩及びその製造方法
JP2012111750A (ja) * 2010-11-02 2012-06-14 Nissan Chem Ind Ltd アミノ安息香酸誘導体の溶媒和物及びその製造方法
WO2013051625A1 (ja) 2011-10-03 2013-04-11 日産化学工業株式会社 多能性幹細胞からの巨核球及び／又は血小板の製造方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146284A1 (en) 2020-05-06 2023-03-15 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
JP2023525513A (ja) 2020-05-06 2023-06-16 セレクティス ソシエテ アノニム 細胞ゲノムにおける外因性配列の標的化挿入のための方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502617A (ja) 1998-02-17 2002-01-29 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
WO2004108683A1 (en) 2003-06-06 2004-12-16 Nissan Chemical Industries, Ltd. 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators
JP2006506452A (ja) * 2002-10-09 2006-02-23 日産化学工業株式会社 ピラゾロン化合物及びトロンボポエチンレセプター活性化剤
JP2006061106A (ja) 2004-08-27 2006-03-09 Hiroo Iwata 造血幹細胞の製造方法
WO2006062240A1 (en) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
WO2006062249A1 (ja) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 置換ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
WO2006062247A1 (ja) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 置換複素環化合物及びトロンボポエチンレセプター活性化剤
WO2006064957A1 (ja) * 2004-12-14 2006-06-22 Nissan Chemical Industries, Ltd. アミド化合物及びトロンボポエチンレセプター活性化剤
WO2007052808A1 (ja) * 2005-11-07 2007-05-10 Nissan Chemical Industries, Ltd. ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
WO2007142308A1 (ja) * 2006-06-07 2007-12-13 Nissan Chemical Industries, Ltd. 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU755344B2 (en) 1998-02-05 2002-12-12 Novartis Ag Expanded and genetically modified populations of human hematopoietic stem cells
US20030044978A1 (en) * 1998-02-05 2003-03-06 Novartis Corporation Expanded and genetically modified populations of human hematopoietic stem cells
EP1424389A4 (en) * 2001-08-07 2004-08-25 Kirin Brewery PROCESS FOR THE PREPARATION OF MULTIPOTENT HEMATOPOIETIC STEM CELLS
EP2228435A4 (en) 2007-12-05 2013-01-23 Nissan Chemical Ind Ltd METHOD FOR AMPLIFYING HEMATOPOIETIC STRAIN CELL USING HETEROCYCLIC COMPOUND
US20100310535A1 (en) 2007-12-05 2010-12-09 Nissan Chemical Industries, Ltd. Method for expanding hematopoietic stem cells using heterocyclic compound

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002502617A (ja) 1998-02-17 2002-01-29 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
JP2006506452A (ja) * 2002-10-09 2006-02-23 日産化学工業株式会社 ピラゾロン化合物及びトロンボポエチンレセプター活性化剤
WO2004108683A1 (en) 2003-06-06 2004-12-16 Nissan Chemical Industries, Ltd. 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators
JP2006527187A (ja) * 2003-06-06 2006-11-30 日産化学工業株式会社 ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
JP2006061106A (ja) 2004-08-27 2006-03-09 Hiroo Iwata 造血幹細胞の製造方法
WO2006062240A1 (en) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
WO2006062249A1 (ja) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 置換ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
WO2006062247A1 (ja) * 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 置換複素環化合物及びトロンボポエチンレセプター活性化剤
WO2006064957A1 (ja) * 2004-12-14 2006-06-22 Nissan Chemical Industries, Ltd. アミド化合物及びトロンボポエチンレセプター活性化剤
WO2007052808A1 (ja) * 2005-11-07 2007-05-10 Nissan Chemical Industries, Ltd. ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
WO2007142308A1 (ja) * 2006-06-07 2007-12-13 Nissan Chemical Industries, Ltd. 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
CASSEL, A. ET AL., EXP. HEMATOL., vol. 21, 1993, pages 585 - 91
CHUTE, JP ET AL., PROC NATL ACAD SCI USA., vol. 103, 2006, pages 11707 - 12
CWIRLA, S.E. ET AL.: "Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine", SCIENCE, vol. 276, no. 5319, 1997, pages 1696 - 1699, XP008136351 *
EMA, H. ET AL., BLOOD, vol. 75, 1990, pages 1941 - 6
ISHIZAWA, L. ET AL., J HEMATOTHER., vol. 2, 1993, pages 333 - 8
KAUSHANSKY, K ET AL., ANN NY ACAD SCI., vol. 1044, 2005, pages 139 - 141
KURTZBERT, J. ET AL., NEW ENG. J. MED., vol. 335, 1996, pages 157 - 66
LAM AC ET AL., TRANSFUSION, vol. 41, no. 12, December 2001 (2001-12-01), pages 1567 - 76
LEUNG, AY ET AL., EXP HEMATOL., vol. 33, 2005, pages 422 - 7
LIU, J. ET AL.: "Ex vivo expansion of enriched CD34+ cells from neonatal blood in the presence of thrombopoietin, a comparison with cord blood and bone marrow", BONE MARROW TRANSPLANT., vol. 24, no. 3, 1999, pages 247 - 252, XP008136342 *
LU, L. ET AL., EXP. HEMATOL., vol. 11, 1983, pages 721 - 9
MILHEM, M ET AL., BLOOD, vol. 103, 2004, pages 4102 - 10
NAKAMURA, T. ET AL.: "A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis", BLOOD, vol. 107, no. 11, 2006, pages 4300 - 4307, XP008136356 *
ORLIC, D ET AL., NATURE, vol. 410, 2001, pages 701 - 5
ROSLER, E ET AL., EXP HEMATOL., vol. 28, 2000, pages 841 - 52
See also references of EP2233561A4 *
SHIMAKURA, Y ET AL., STEM CELLS, vol. 18, 2000, pages 183 - 9
TAGUCHI, A ET AL., J CLIN INVEST., vol. 114, 2004, pages 330 - 8
TATEISHI-YUYAMA, E ET AL., LANCET, vol. 360, 2002, pages 427 - 35

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5573159B2 (ja) * 2007-12-05 2014-08-20 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
JPWO2009072624A1 (ja) * 2007-12-05 2011-04-28 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
JPWO2009072625A1 (ja) * 2007-12-05 2011-04-28 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
JP5573160B2 (ja) * 2007-12-05 2014-08-20 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
EP2439204A1 (en) * 2009-06-04 2012-04-11 Nissan Chemical Industries, Ltd. Heterocyclic compound and hematopoietic stem cell amplifier
EP2439204A4 (en) * 2009-06-04 2012-06-20 Nissan Chemical Ind Ltd HETEROCYCLIC CONNECTION AND HEMATOPOIETIC STEM CELL AMPLIFIER
WO2010140685A1 (ja) * 2009-06-04 2010-12-09 日産化学工業株式会社 ヘテロ環化合物及び造血幹細胞の増幅剤
US9328085B2 (en) 2009-06-04 2016-05-03 Nissan Chemical Industries, Ltd. Heterocyclic compounds and expansion agents for hematopoietic stem cells
JP2012111750A (ja) * 2010-11-02 2012-06-14 Nissan Chem Ind Ltd アミノ安息香酸誘導体の溶媒和物及びその製造方法
WO2012060388A1 (ja) * 2010-11-02 2012-05-10 日産化学工業株式会社 アミノ安息香酸誘導体の有機アミン塩及びその製造方法
US8946286B2 (en) 2010-11-02 2015-02-03 Nissan Chemical Industries, Ltd. Organic amine salts of aminobenzoic acid derivatives and method for producing same
RU2569885C2 (ru) * 2010-11-02 2015-12-10 Ниссан Кемикал Индастриз, Лтд. Органические аминные соли производных аминобензойной кислоты и способ их получения
JP5892069B2 (ja) * 2010-11-02 2016-03-23 日産化学工業株式会社 アミノ安息香酸誘導体の有機アミン塩及びその製造方法
WO2013051625A1 (ja) 2011-10-03 2013-04-11 日産化学工業株式会社 多能性幹細胞からの巨核球及び／又は血小板の製造方法
KR20140082673A (ko) 2011-10-03 2014-07-02 닛산 가가쿠 고교 가부시키 가이샤 다능성 간세포로부터의 거핵구 및/또는 혈소판의 제조 방법

Also Published As

Publication number Publication date
JP5573161B2 (ja) 2014-08-20
US9115341B2 (en) 2015-08-25
KR101585276B1 (ko) 2016-01-13
EP2233561A4 (en) 2013-01-16
KR20100098522A (ko) 2010-09-07
JPWO2009072626A1 (ja) 2011-04-28
US20100310537A1 (en) 2010-12-09
EP2233561A1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
WO2009072624A1 (ja) ヘテロ環化合物による造血幹細胞の増幅方法
WO2009072626A1 (ja) ヘテロ環化合物による造血幹細胞の増幅方法
WO2009072625A1 (ja) ヘテロ環化合物による造血幹細胞の増幅方法
WO2009072635A1 (ja) ヘテロ環化合物による造血幹細胞の増幅方法
SG179207A1 (en) Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
MX356756B (es) Células madre pluripotentes en microportadores.
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
MX340490B (es) Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
MX2008013582A (es) Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
IN2012DN00755A (ja)
WO2008051568A3 (en) Methods and compositions for treatment of bone defects with placental cell populations
ATE508747T1 (de) C-kit kinase-hemmer
NZ579928A (en) Fluorinated derivatives of deferiprone
WO2008116107A3 (en) Piperazine derivatives as glucokinase activators
TW200616976A (en) Pyrimidine derivatives
NZ599138A (en) Purine derivatives useful as hsp90 inhibitors
TW200745137A (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
WO2008137816A8 (en) Tricyclic compounds as matrix metalloproteinase inhibitors
HK1125291A1 (en) Method of using guava extract and composition including guava extract
WO2008114812A1 (ja) Jak阻害剤
WO2007143117A3 (en) Differentiation of primate pluripotent cells to hepatocyte-lineage cells
EP2581442A4 (en) PROCESS FOR PRODUCING HEMATOPOIETIC STEM CELLS
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
MX339403B (es) Uso de compuesto que libera peroxigeno libre de nitrogeno para reducir el crecimiento de microorganismos contaminantes en la fermentacion de etanol.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08856980

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009544754

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20107012339

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008856980

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12746507

Country of ref document: US